Human alpha1-proteinase inhibitor (A1PI) (Prolastin®)

Assessment Status Assessment process complete.
Drug Human alpha1-proteinase inhibitor (A1PI)
Brand Prolastin®
Indication For long-term augmentation therapy in subjects with alpha1-proteinase inhibitor deficiency (phenotypes PiZZ, PiZ(null), Pi (null,null) and PiSZ) within the limits of moderate airflow obstruction (FEV1 35-60%) and the evaluation of the clinical condition (disability).
Assessment Process
Rapid review commissioned 05/05/2017
Rapid review outcome Full Pharmacoeconomic Evaluation Recommended at the Submitted Price.

The company has not submitted a HTA dossier to the NCPE therefore the cost effectiveness of the technology could not be proven.